Results 151 to 160 of about 81,723 (303)

Refractory mogamulizumab-associated rash responding to an oral Janus kinase inhibitor

JAAD Case Reports, 2023
Carine M. Lama, MS, Miguel A. Hernandez-Rovira, BSc, Neha Mehta-Shah, MD, Aaron Russell, MD, Amy C.M. Musiek, MD   +4 more
doaj   +1 more source

Tapinarof as a Therapeutic Aryl Hydrocarbon Receptor‐Modulating Agent in the Treatment of Atopic Dermatitis

The Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory dermatitis underpinned by Type 2 inflammation driven by cytokines such as IL‐4 and IL‐13. It is characterized by skin barrier dysfunction, Th2 immune deviation, and pruritus. While biologics and oral Janus kinase (JAK) inhibitors demonstrate high therapeutic efficacy by targeting cytokines that ...
Gaku Tsuji, Yoko Fuyuno, Koji Kawamura, Ayako Yumine, Masaki Takemura, Yasutaka Mitamura, Kazuhiko Yamamura, Takeshi Nakahara   +7 more
wiley   +1 more source

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel, Peter Foley, Kathryn A. Gibson, Anita Townsend, Gabrielle Louise Reppen, William Romero Gallardo   +5 more
wiley   +1 more source

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

Allergy, EarlyView.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh, Lior Seluk, Philipp Bosch, Carolina Aguiar, Jens Thiel, Bernhard Hellmich, Michael E. Wechsler, Salman Siddiqui   +7 more
wiley   +1 more source

Janus kinase inhibitor and rituximab in rheumatoid arthritis: is it a safe combination? [PDF]

Rheumatol Adv Pract
Rabee H, Mahto A.
europepmc   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Use of Janus Kinase Inhibitor Upadacitinib in Microscopic Colitis. [PDF]

ACG Case Rep J
Mumm B, Stein DJ.
europepmc   +1 more source

Non‐Invasive Scalp Tape‐Strip RNA Sequencing Captures Disease Activity and Treatment‐Response Signatures in Alopecia Areata

Allergy, EarlyView.
Non‐invasive scalp tape‐strip RNA sequencing captures core immune and follicular molecular signatures in alopecia areata. Tape‐strip transcriptomic profiles reflect disease severity and treatment response to baricitinib, with concordance to scalp biopsy‐derived signatures.
Carmen Mochón‐Jiménez, Jesús Gay‐Mimbrera, Viviana Dávila‐Flores, Helen He, Jerry Zhou, Irene Rivera‐Ruiz, Pedro J. Gómez‐Arias, Juan de Luque‐Fernández, Benjamin Ungar, Emma Guttman‐Yassky, Juan Ruano   +10 more
wiley   +1 more source

Diversifying the triquinazine scaffold of a Janus kinase inhibitor. [PDF]

RSC Med Chem
Mulliri K, Meier K, Feuchter JD, Javor S, Meirelles MA, Reymond JL.   +5 more
europepmc   +1 more source

Early Epidemiologic and Immune Predictors of Atopic Dermatitis: Reduced Cord Blood Regulatory B10 Cells in the Munich Atopy Prediction Study (MAPS)

Allergy, EarlyView.
In this prospective birth cohort from Munich, comprehensive clinical assessments and longitudinal lifestyle questionnaires were combined with cord blood immune profiling. Infants who later developed AD showed altered cord blood immune signatures, including reduced CD4+ T cells, increased B cells and markedly decreased Breg cells. Epidemiologic factors,
S. Preis, S. Kaesler, M. Koeberle, M. Hils, B. Evers, R. L. Silva, Y. Skabytska, L. Schellenberger, H. Hufnagel, M. Schielein, B. Kuschel, Y. Amar, A. Zink, T. Biedermann, Z. Kurgyis   +14 more
wiley   +1 more source